Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FADS1 | O60427 | 3/20 | 1.00 |
| ▸ | EGFR | P00533 | 3/20 | 0.69 |
| ▸ | KDR | P35968 | 4/20 | 0.62 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.61 |
| ▸ | PTK6 | Q13882 | 1/20 | 0.61 |
| ▸ | LCK | P06239 | 1/20 | 0.59 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.57 |
| ▸ | DNMT3A | Q9Y6K1 | 1/20 | 0.57 |
| ▸ | CA9 | Q16790 | 1/20 | 0.56 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.54 |
| ▸ | GAK | O14976 | 1/20 | 0.53 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.53 |
| ▸ | COQ8A | Q8NI60 | 1/20 | 0.53 |
| ▸ | NLK | Q9UBE8 | 1/20 | 0.53 |
| ▸ | APP | P05067 | 1/20 | 0.53 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | ATM | Q13315 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4738631 | 0.91 | FADS1 (0.83) | FADS1EGFRKDRERBB2PTK6 | |
| Metaquine SCHEMBL7205743 | 0.83 | FADS1 (0.71) | FADS1CA9GAKAPPNR4A2 | |
| SCHEMBL4740996 | 0.83 | FADS1 (0.71) | FADS1EGFRKDRERBB2PTK6 | |
| SCHEMBL15614056 | 0.83 | FADS1 (0.71) | FADS1EGFRKDRERBB2PTK6 | |
| SCHEMBL19633659 | 0.83 | ALK (0.72) | FADS1EGFRERBB2PTK6CA9 | |
| SCHEMBL19633641 | 0.83 | FADS1 (0.71) | FADS1EGFRERBB2PTK6CA9 | |
| SCHEMBL30307407 | 0.83 | FADS1 (0.70) | FADS1EGFRKDRERBB2DNMT1 | |
| SCHEMBL170830 | 0.82 | ERBB2 (0.73) | FADS1EGFRERBB2DNMT1DNMT3A | |
| SCHEMBL30420824 | 0.82 | ERBB2 (0.73) | FADS1EGFRERBB2DNMT1DNMT3A | |
| SCHEMBL4882303 | 0.82 | EGFR (0.69) | FADS1EGFRKDRERBB2PTK6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008089310-A2 | DELTA 5 DESATURASE INHIBITORS FOR THE TREATMENT OF OBESITY | LEXICON PHARMACEUTICALS, INC. (US) | 2008-07-24 | — | — | WO | claimed |
| WO-2008089307-A2 | DELTA 5 DESATURASE INHIBITORS FOR THE TREATMENT OF PAIN, INFLAMMATION AND CANCER | LEXICON PHARMACEUTICALS, INC. (US) | 2008-07-24 | — | — | WO | claimed |
| US-20240216316-A1 | DIHOMO-GAMMA LINOLENIC ACID (DGLA) IS A NOVEL SENOLYTIC | BUCK INST RES AGING (US) | 2024-07-04 | — | — | US | disclosed |
| CN-115947684-A | Method for preparing 4-aminoquinoline derivatives through palladium and copper concerted catalytic oxidation aromatization | 贵州医科大学 | 2023-04-11 | — | — | CN | disclosed |
| US-20080200458-A1 | Methods and compositions for the treatment of body composition disorders | LEXICON PHARMACEUTICALS, INC. | 2008-08-21 | — | — | US | disclosed |
| US-20080194557-A1 | Methods and compositions for the treatment of pain, inflammation and cancer | LEXICON PHARMACEUTICALS, INC. | 2008-08-14 | — | — | US | disclosed |
| WO-2008089310-A2 | DELTA 5 DESATURASE INHIBITORS FOR THE TREATMENT OF OBESITY | LEXICON PHARMACEUTICALS, INC. (US) | 2008-07-24 | — | — | WO | disclosed |
| WO-2008089307-A2 | DELTA 5 DESATURASE INHIBITORS FOR THE TREATMENT OF PAIN, INFLAMMATION AND CANCER | LEXICON PHARMACEUTICALS, INC. (US) | 2008-07-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194557-A1 | Methods and compositions for the treatment of pain, inflammation and cancer | TNF, IL6, CXCL8 | FADS1 1059/4885EGFR 1259/4885KDR 1066/4885 |
| US-20240216316-A1 | DIHOMO-GAMMA LINOLENIC ACID (DGLA) IS A NOVEL SENOLYTIC | DAGLA, DAGLB, MGLL | FADS1 192/4885EGFR 2964/4885KDR 4593/4885 |
| US-20080200458-A1 | Methods and compositions for the treatment of body composition disorders | CPT1B, CPT1A, SHBG | FADS1 270/4885EGFR 3860/4885KDR 4840/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.